This appeal was fully successful
The AAO sustained the appeal, finding that the petitioner met three of the ten evidentiary criteria (original business contributions of major significance, leading/critical role, and high salary) and passed the final merits determination as an extraordinary ability individual in business.
Next step: a full merits review weighing all the evidence together.
A senior executive with 27 years of experience in vaccine business strategy and development appealed SCOPS's denial of his EB-1A petition. SCOPS had found only two of the required three criteria met (leading role and high salary) and rejected his claim of original business contributions. The AAO reversed the denial, finding that detailed expert letters from former NIH officials, pharmaceutical executives, a former Texas Governor, and a former HHS Assistant Secretary—corroborated by media coverage—demonstrated that his multibillion-dollar transactions, pandemic preparedness partnerships, and vaccine manufacturing initiatives constituted original contributions of major significance. The AAO also conducted a final merits determination and found the petitioner qualifies as an individual of extraordinary ability in business.
What worked: Highly detailed expert opinion letters from prominent figures (former NIH director, former government officials, senior pharmaceutical executives) that specifically described the petitioner's contributions and their broader public health impact were decisive. Corroborating evidence such as press coverage of major deals and invitations to speak at industry forums bolstered the expert testimony. The combination of a 27-year track record, multibillion-dollar deals, and documented contributions to pandemic preparedness established sustained acclaim at the very top of the field.
What failed: Evidence for the membership criterion (outstanding achievement-based associations) and the published materials criterion (professional/trade publications or major media) was found insufficient and was not contested on appeal. SCOPS initially found that the petitioner's business contributions had not extended beyond his employer's sphere, though the AAO reversed this finding.
Takeaway: For business executives whose work is largely 'behind the scenes,' assembling highly specific expert letters from recognized external authorities—government officials, academic leaders, and industry peers—that detail both the nature of contributions and their broader field-wide or public-health impact is critical to satisfying the original contributions criterion. Corroborating those letters with press coverage, press releases, and speaking invitations strengthens the case significantly.
Cases like this are frequently used by attorneys when responding to RFEs or building initial petitions. The evidence patterns that worked (or failed) here directly reflect what USCIS officers look for when evaluating EB-1A criteria.
● Evidence that moved the needle
- Highly detailed expert opinion letters from prominent figures (former NIH director, former government officials, senior pharmaceutical executives) that specifically described the petitioner's contributions and their broader public health impact were decisive
- Corroborating evidence such as press coverage of major deals and invitations to speak at industry forums bolstered the expert testimony
- The combination of a 27-year track record, multibillion-dollar deals, and documented contributions to pandemic preparedness established sustained acclaim at the very top of the field.
● Evidence that wasn't enough alone
- Evidence for the membership criterion (outstanding achievement-based associations) and the published materials criterion (professional/trade publications or major media) was found insufficient and was not contested on appeal
- SCOPS initially found that the petitioner's business contributions had not extended beyond his employer's sphere, though the AAO reversed this finding.
Criterion-by-criterion breakdown
Membership in associations requiring outstanding achievement
Not metPetitioner did not contest SCOPS' finding that membership criterion was not satisfied on appeal.
Published material about the person
Not metPetitioner did not contest SCOPS' finding that published materials criterion was not satisfied on appeal.
Original contributions of major significance
Reversed in their favorAAO reversed SCOPS' denial; found that detailed expert letters corroborated by media coverage and other documentation established original business contributions of major significance, including multibillion-dollar deals, pandemic preparedness partnerships, and vaccine manufacturing facilities.
Leading or critical role for distinguished organizations
MetSCOPS found this criterion met; petitioner served as VP and General Counsel for Vaccine Business Development at a major pharmaceutical company and held board and management team positions.
High salary or other significantly high remuneration
MetSCOPS found this criterion met; petitioner commanded a high salary relative to others in the field.
Completed
I-140 filed
Senior executive specializing in vaccine business strategy and development, including mergers, acquisitions, and public-private partnerships in the pharmaceutical/vaccine sector
Completed
SCOPS — Denied
Initial decision: Denied.
Completed
Appeal to the AAO
Petitioner appealed to the Administrative Appeals Office for de novo review.
2026-02-20
AAO decision — Sustained
The AAO sustained the appeal, finding that the petitioner met three of the ten evidentiary criteria (original business contributions of major significance, leading/critical role, and high salary) and passed the final merits determination as an extraordinary ability individual in business.